Neogen (NEOG) Aktienübersicht
Die Neogen Corporation entwickelt, produziert und vermarktet verschiedene Produkte und Dienstleistungen für die Lebensmittel- und Tiersicherheit in den Vereinigten Staaten und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
NEOG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Neogen Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$9.75 |
| 52-Wochen-Hoch | US$11.43 |
| 52-Wochen-Tief | US$4.56 |
| Beta | 1.79 |
| 1 Monat Veränderung | 4.95% |
| 3 Monate Veränderung | 3.50% |
| 1 Jahr Veränderung | 74.73% |
| 3 Jahre Veränderung | -56.61% |
| 5 Jahre Veränderung | -78.01% |
| Veränderung seit IPO | 3,715.15% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Jun 27
Neogen: Still A Difficult Story
Summary Neogen has addressed urgent deleveraging needs through divestments and cost-cutting, but earnings power remains modest, and recent divestments were at low sales multiples. Q3 results were mixed: core food safety sales grew 4%, the animal segment fell 8% due to a supplier issue, and adjusted EBITDA margin rose to 22.8%. The $160M genomics business sale to Zoetis reduces net debt below $500M but was completed at only 1.5x sales, reflecting lagging margins and limited immediate value creation. Pro forma sales are now ~$800M, with realistic earnings estimates of $0.30-$0.45/share; organic growth and margin improvement remain critical for re-rating. Read the full article on Seeking Alpha
Narrativ-Update • Jun 23
NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook
Analysts have modestly revised their Neogen price target to $13.00, reflecting updated assumptions around a slightly lower discount rate, softer revenue growth expectations, reduced profit margins, and a higher future P/E multiple in their valuation models. What's in the News for Neogen Neogen expanded FIFRA Section 2(ee) recommendations for its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol products to support New World Screwworm response efforts in livestock, with approvals in Texas and availability in Florida.
Narrativ-Update • Jun 08
NEOG: Food Safety Execution And Manufacturing Shift Will Support Future Upside
Analysts have raised their price target on Neogen to $11.00. This reflects updated assumptions that include a slightly lower discount rate, a smaller expected decline in revenue growth, a marginally higher profit margin, and a modestly reduced future P/E multiple.Recent updates
Seeking Alpha • Jun 27
Neogen: Still A Difficult Story
Summary Neogen has addressed urgent deleveraging needs through divestments and cost-cutting, but earnings power remains modest, and recent divestments were at low sales multiples. Q3 results were mixed: core food safety sales grew 4%, the animal segment fell 8% due to a supplier issue, and adjusted EBITDA margin rose to 22.8%. The $160M genomics business sale to Zoetis reduces net debt below $500M but was completed at only 1.5x sales, reflecting lagging margins and limited immediate value creation. Pro forma sales are now ~$800M, with realistic earnings estimates of $0.30-$0.45/share; organic growth and margin improvement remain critical for re-rating. Read the full article on Seeking AlphaNarrativ-Update • Jun 23
NEOG: Screwworm Response And Buybacks Will Support Bullish 2026 Outlook
Analysts have modestly revised their Neogen price target to $13.00, reflecting updated assumptions around a slightly lower discount rate, softer revenue growth expectations, reduced profit margins, and a higher future P/E multiple in their valuation models. What's in the News for Neogen Neogen expanded FIFRA Section 2(ee) recommendations for its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol products to support New World Screwworm response efforts in livestock, with approvals in Texas and availability in Florida.Narrativ-Update • Jun 08
NEOG: Food Safety Execution And Manufacturing Shift Will Support Future Upside
Analysts have raised their price target on Neogen to $11.00. This reflects updated assumptions that include a slightly lower discount rate, a smaller expected decline in revenue growth, a marginally higher profit margin, and a modestly reduced future P/E multiple.Narrativ-Update • May 25
NEOG: Raised 2026 Revenue Guidance And Higher P/E Expectation Will Support Upside
Analysts have raised their price target for Neogen to $11.00 from $10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher expected future P/E multiple. What's in the News Neogen issued updated guidance for fiscal 2026, focusing on its outlook for full year revenue (Key Developments).
Narrativ-Update • Apr 30
NEOG: Updated 2026 Revenue Outlook Will Support Future Upside Potential
Analysts have nudged their price target on Neogen slightly higher to $12, reflecting updated assumptions around discount rate, profit margin and future P/E that keep fair value broadly in line with prior estimates. What's in the News Neogen updated full fiscal year 2026 guidance, with projected revenue now in a range of $857 million to $860 million.Narrativ-Update • Apr 15
NEOG: Recall Response And Updated 2026 Guidance Will Support Future Upside
Analysts have raised their price target on Neogen from $11.67 to $12.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a higher future P/E of 32.21 compared with 28.61 previously. What's in the News Neogen updated full fiscal year 2026 guidance, indicating expected revenue in a range of $857 million to $860 million, compared with prior guidance of $845 million to $855 million (corporate guidance).Narrativ-Update • Apr 01
NEOG: Earnings Outlook Will Benefit From Recall Actions And New Guidance
Analysts have raised their price target on Neogen from $8.17 to $11.67 per share, citing updated assumptions related to the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials.Narrativ-Update • Mar 18
NEOG: Recall Resolution Will Shape Bullish View On 2026 Revenue Outlook
Analysts have kept Neogen's price target steady at $13.00, indicating only minor adjustments in assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL / 50 mg vials, and is extending the recall to 2 mL / 20 mg vials while its investigation continues (Key Developments).Narrativ-Update • Mar 04
NEOG: 2026 Outlook Will Rely On Recall Resolution For Upside
Analysts are holding Neogen's fair value estimate at $13.00 while modestly adjusting their assumptions around the discount rate, long term revenue trends, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the overall price target level.Narrativ-Update • Feb 18
NEOG: 2026 Revenue Outlook Will Support Continued Bullish Thesis
Analysts have maintained Neogen's price target at $13.00, noting that only minor adjustments to assumptions around discount rate, revenue growth, profit margins, and future P/E were made, which do not materially change their valuation view. What's in the News Neogen is voluntarily recalling all lots of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level, after microbial contamination was identified in certain 10 mL/50 mg vials used via intraarticular injection, which is inconsistent with the product's labeled use (Key Developments).Narrativ-Update • Feb 03
NEOG: Higher Forward P/E And 2026 Outlook Will Support Bullish Thesis
Analysts have raised their price target on Neogen by an implied $3 per share, pointing to adjustments in fair value, discount rate, revenue growth expectations, profit margin assumptions, and a higher forward P/E multiple as the key drivers behind the change. What's in the News Neogen is voluntarily recalling all lots within expiry of Neogen Vet HYCOAT Hyaluronate Sodium Sterile Solution for dogs, cats, and horses at the veterinarian level due to microbial contamination identified in certain 10 mL/50 mg vials, with an expanded recall to 2 mL/20 mg vials while the investigation continues (Key Developments).Analyseartikel • Feb 02
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 46% Jump Looks Justified
Despite an already strong run, Neogen Corporation ( NASDAQ:NEOG ) shares have been powering on, with a gain of 46% in...Narrativ-Update • Jan 20
NEOG: Future CFO Transition And 2026 Guidance Will Support Measured Outlook
Analysts have raised their fair value estimate for Neogen from US$6.50 to US$10.00, reflecting updated assumptions regarding discount rates, revenue trends, profit margins and a higher future P/E multiple. What's in the News Neogen issued earnings guidance for fiscal 2026, with revenue anticipated in the range of US$845 million to US$855 million, giving investors a sense of management’s current expectations for the business (Key Developments).Narrativ-Update • Jan 05
NEOG: New CFO Appointment Will Support Confidence In Earnings Outlook
Analysts now place a higher implied value on Neogen, lifting their fair value estimate from US$8.00 to US$10.00, citing updated assumptions around discount rates, revenue trends, profit margins, and a richer future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer, effective November 3, 2025.Analyseartikel • Dec 19
Neogen Corporation (NASDAQ:NEOG) Shares Fly 34% But Investors Aren't Buying For Growth
The Neogen Corporation ( NASDAQ:NEOG ) share price has done very well over the last month, posting an excellent gain of...Narrativ-Update • Dec 17
NEOG: Future CFO Transition And Guidance Stability Will Support Measured Outlook
Analysts have raised their price target on Neogen from approximately $5.00 to $6.50 per share, citing a slightly lower discount rate, modestly improved revenue trajectory, better profit margin expectations, and a willingness to assign a higher future P/E multiple. What's in the News Neogen appointed Bryan Riggsbee as Chief Financial Officer effective November 3, 2025, with outgoing CFO David Naemura supporting the transition through year end.Narrativ-Update • Dec 03
NEOG: CFO Transition And Alliance Renewal Will Support Future Earnings
Analysts have modestly raised their price target on Neogen by about $0.20 per share, citing a slightly higher assumed discount rate and marginally richer future valuation multiples that together offset minor tweaks to long term growth and margin expectations. What's in the News Reaffirmed fiscal 2026 earnings guidance, maintaining full-year revenue expectations of $820 million to $840 million (company guidance).Narrativ-Update • Nov 19
NEOG: Profit Margin Expansion And CFO Transition Will Drive Earnings Potential
Analysts have raised their price target for Neogen modestly, citing improved profit margin projections and a slightly lower expected future price-to-earnings ratio as key factors behind the adjustment. What's in the News Neogen appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025.Narrativ-Update • Oct 31
NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion
Narrative Update: Neogen Analyst Price Target Revised Analysts have slightly raised their price target for Neogen, citing improvements in expected profit margins and a modest decline in projected future valuation multiples. This has resulted in a new estimated fair value of $8.17 per share.Narrativ-Update • Oct 17
Food Safety Testing Advances Will Expand Global Opportunities
Neogen's analyst target price has risen from $7.67 to $8.17, as analysts point to improved revenue growth projections alongside a reduced discount rate, both supporting a higher valuation. What's in the News Neogen introduced Molecular Detection Assay: Listeria Right Now, a rapid, enrichment-free tool for detecting Listeria species with results in about two hours and streamlined workflow benefits (Product-Related Announcements).Narrativ-Update • Oct 03
Food Safety Testing Advances Will Expand Global Opportunities
Analysts have raised their price target for Neogen from $6.50 to $7.67, citing a slightly lower discount rate and forward profit expectations. Revenue growth projections remain stable.Analyseartikel • Jul 10
Is Neogen (NASDAQ:NEOG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Neues Narrativ • May 27
Food Safety And Genomics Will Expand Global Markets
Resilient core businesses, strategic divestitures, and efficiency initiatives are expected to stabilize revenue and expand margins as macro and operational conditions improve.Analyseartikel • May 16
Improved Revenues Required Before Neogen Corporation (NASDAQ:NEOG) Stock's 33% Jump Looks Justified
Those holding Neogen Corporation ( NASDAQ:NEOG ) shares would be relieved that the share price has rebounded 33% in the...Seeking Alpha • Apr 23
Neogen: A Fair Divestment (Rating Upgrade)
Summary Neogen's merger with 3M Food Safety led to significant debt and operational struggles, causing shares to plummet and the CEO to be ousted. Following disappointing sales and earnings, the company is exploring asset sales and restructuring, offering potential upside if stabilization occurs. Neogen's current valuation appears modest relative to sales, presenting a speculative opportunity for investors willing to take on risk. I am cautiously optimistic about Neogen's future, considering the potential for above-average returns if divestments are executed at reasonable valuations. Read the full article on Seeking AlphaAnalyseartikel • Apr 11
Here's Why Neogen (NASDAQ:NEOG) Is Weighed Down By Its Debt Load
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Jan 14
Neogen: Food Safety Play Is Far From A Safe Pay
Summary Neogen Corporation's merger with 3M Food Safety in 2022 led to significant challenges, including valuation compression, debt increase, and underperformance, causing shares to plummet. Neogen's financial performance has been disappointing, with sales and EBITDA falling short of expectations and net debt increasing. The company's guidance for 2025 remains modest, and recent results have shown minimal revenue growth and high leverage ratios, frustrating investors. Trading at $12, NEOG's future hinges on management's ability to execute and deliver on promised EBITDA improvements to reduce leverage and boost earnings. Read the full article on Seeking AlphaAnalyseartikel • Dec 03
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
It's not a stretch to say that Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 3.3x right now...Analyseartikel • Nov 07
Does Neogen (NASDAQ:NEOG) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Oct 11
Neogen Stock: Expect Volatility To Continue Amid Weak Growth
Summary Neogen reported its Q1 earnings, which missed expectations. Weak demand trends across food and animal safety end markets have pressured the sales outlook. We expect shares to remain volatile until there is evidence of a growth rebound. Read the full article on Seeking AlphaAnalyseartikel • Aug 28
Risks To Shareholder Returns Are Elevated At These Prices For Neogen Corporation (NASDAQ:NEOG)
Neogen Corporation's ( NASDAQ:NEOG ) price-to-sales (or "P/S") ratio of 4x may not look like an appealing investment...Analyseartikel • Jul 31
We Think Neogen (NASDAQ:NEOG) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Aktionärsrenditen
| NEOG | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 4.4% | -1.5% | 0.6% |
| 1Y | 74.7% | -19.9% | 19.5% |
Rendite im Vergleich zur Industrie: NEOG übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -19.9 erzielte.
Rendite vs. Markt: NEOG übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19.5 erzielte.
Preisvolatilität
| NEOG volatility | |
|---|---|
| NEOG Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: NEOG hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: NEOGDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1981 | 2,974 | Mike Nassif | www.neogen.com |
Die Neogen Corporation entwickelt, produziert und vermarktet verschiedene Produkte und Dienstleistungen für die Lebensmittel- und Tiersicherheit in den Vereinigten Staaten und international. Das Unternehmen ist in zwei Segmenten tätig: Lebensmittelsicherheit und Tiersicherheit. Das Segment Lebensmittelsicherheit bietet diagnostische Testkits und ergänzende Produkte zum Nachweis gefährlicher und unbeabsichtigter Substanzen in Lebens- und Futtermitteln an, darunter lebensmittelbedingte Krankheitserreger, Verderbniserreger, natürliche Toxine, Lebensmittelallergene, Nebenprodukte von Wiederkäuern, Fleischspeziationen, Arzneimittelrückstände, Pestizidrückstände und allgemeine Hygienemängel sowie Lebensmittelqualität und Nährwertkomponenten.
Neogen Corporation's Grundlagenzusammenfassung
| NEOG grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.02b |
| Gewinn(TTM) | -US$608.84m |
| Umsatz(TTM) | US$870.56m |
2.4x
Kurs-Umsatz-Verhältnis-3.5x
Kurs-Gewinn-Verhältnis Ist NEOG zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| NEOG Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$870.56m |
| Kosten der Einnahmen | US$476.99m |
| Bruttogewinn | US$393.58m |
| Sonstige Ausgaben | US$1.00b |
| Gewinn | -US$608.84m |
Zuletzt gemeldete Gewinne
Feb 28, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -2.80 |
| Bruttomarge | 45.21% |
| Nettogewinnspanne | -69.94% |
| Schulden/Eigenkapital-Verhältnis | 37.8% |
Wie hat sich NEOG auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/09 04:56 |
| Aktienkurs zum Tagesende | 2026/07/09 00:00 |
| Gewinne | 2026/02/28 |
| Jährliche Einnahmen | 2025/05/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Neogen Corporation wird von 16 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Robert Labick | CJS Securities, Inc. |
| David Westenberg | CL King & Associates, Inc. |